A Phase 1, Open-label Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TAS-102 in Patients With Advanced Solid Tumors and Varying Degrees of Hepatic Impairment.
Phase of Trial: Phase I
Latest Information Update: 06 Jun 2017
At a glance
- Drugs Tipiracil/trifluridine (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Expanded access; Pharmacokinetics
- Sponsors Taiho Oncology
- 06 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
- 13 Oct 2016 Status changed from active, no longer recruiting to completed.
- 27 Apr 2016 Status changed from recruiting to active, no longer recruiting.